Noel Clarke: Well, this is a humble interpretation of some data from STAMPEDE and others. Thank you, Matt, for that, and good morning everybody. I’m going to talk about the optimal treatment of newly diagnosed metastatic prostate cancer, building on some of the information that we’ve just seen. We’ve been lucky. We’ve had a lot […]
Chris Sweeney: So I’ve been given the charge of which systemic therapy for which patient with newly diagnosed metastatic prostate cancer. Here are my disclosures, because I’m going to be talking about a number of different drugs. So my goal is to have a high level summary of the eight systemic trials in this space, […]
San Francisco, CA (UroToday.com) — The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its prostate cancer and solid tumor portfolios will be featured at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain. Among Janssen’s 12 accepted abstracts are an oral presentation reporting […]
Eric Small: Thank you very much. Thank you very much. Also, I need to add my thanks of course to Silke and Aurelius. You have a room full of fans, you guys. So thank you for putting on a spectacular meeting. So we’re changing gears here a little bit. I just want people to be […]
Piet Ost: Thank you. Thank you for the nice introduction and the nice invitation. This is a lovely city of Ghent where I am from. Also very lovely to visit. And my Twitter handle is on there, so please tweet a lot. I need the chocolates to bribe the two kids, more on the picture. […]
Karim Fizazi: Thank you very much. Good evening everybody. Thank you for staying. It’s late. But no worries, just relax. This is going to be a short talk and soon you will have a nice apéro and a good dinner with friends. So that’s very nice. This is about access to treatments. I’m not a […]
Mark Rubin: I’d like to thank Aurelius and Silke for inviting me to this meeting. And so, today I’m going to very briefly talk to you about the future of biomarkers in the context of pathologists who’s joining this meeting. And I just want to say as a comment that it’s really, I think, humbling […]
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations Condition: Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer Intervention: Drug: Nivolumab Drug: Ipilimumab Purpose: This study will attempt to determine the efficacy of checkpoint inhibitor immunotherapy with nivolumab and ipilimumab combination therapy followed by nivolumab monotherapy in patients with metastatic prostate cancer harboring loss of […]
Prior studies have demonstrated that fibroblast receptor 3 (FGFR3)-mutant urothelial cancers (UCs) are associated with decreased T-cell infiltration. As FGFR3 mutations are enriched in luminal-like UC and luminal-like UC has been shown to be relatively less responsive to PD-1/PD-L1 inhibition (checkpoint inhibition [CPI]), these data have led to the speculation that FGFR3 mutations may be […]
Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199) Condition: Metastatic Castration-resistant Prostate Cancer Intervention: Biological: Pembrolizumab Drug: Enzalutamide Purpose: This is a study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer (mCRPC). Participants will be enrolled into one of five cohorts: Cohort 1 (participants with programmed […]
